ARBORXR
7.10.2021 16:55:09 CEST | Business Wire | Press release
ArborXR , the leading enterprise AR/VR device management and content distribution platform, and AR/VR solutions distributor, Matts Digital , today announced a partnership to provide frictionless extended reality (XR) solutions at scale in Europe and beyond. With ArborXR’s mobile device management (MDM) software, Matts Digital will help companies securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset user experience. The partnership illustrates an accelerated shift to remote work and training amid the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005755/en/
According to Forbes , global spending on AR/VR rose to $12 billion in 2020, up 50 percent from 2019.
“ArborXR and Matts Digital share a mission to help companies use and scale XR technology with ease, while offering exceptional customer service,” said ArborXR Co-Founder Will Stackable. “By partnering with Matts Digital, ArborXR is able to help global enterprise companies succeed and increase efficiency through the power of XR. We’re thrilled to enter the European market and provide vital software to help companies deploy AR/VR with confidence.”
Matts Digital offers an extensive range of AR/VR products, in addition to unique XR technology professional services. By utilizing ArborXR’s software, Matts Digital will help companies manage thousands of devices with security and control.
“Matts Digital is pleased to work with ArborXR to offer best-in-class XR solutions for a variety of global companies. Together, we will help customers use XR devices with confidence and achieve our shared goal to increase the simplicity, security and efficiency of XR in the workplace,” Matts Digital President Stephane Courgeon said.
To learn more about ArborXR or Matts Digital, visit ArborXR.com or Matts-Digital.com .
About ArborXR
ArborXR is AR/VR mobile device management (MDM) software that allows enterprise companies to securely manage fleets of XR devices, deploy apps and files remotely, and control the in-headset experience. It is used by Fortune 500 companies, businesses, and hundreds of independent software vendors to seamlessly manage devices, enroll and provision headsets, deploy apps and files remotely, and lock down the user experience with kiosk mode and a multi-app launcher. Learn more about ArborXR and its recent completion of a Series A at ArborXR.com .
About Matts Digital
Matts Digital is a Value-Added distributor, specializing in Virtual Reality (VR) and Augmented Reality (AR) solutions. We offer a full range of headsets, peripherals, accessories and hygiene products, as well as unique professional services in this area. Our significant industrial and logistical capacity allows our customers to easily consider the deployment of their ARVR projects on a large scale, in France and abroad. Learn more at Matts-Digital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom